Searchable abstracts of presentations at key conferences in endocrinology

ea0016p523 | Obesity | ECE2008

Obesity in GDM: a registry of GDM in Portugal

Ruas Luisa , Paiva Sandra , Rocha Tiago , Dores Jorge , Carvalheiro Manuela

Introduction: A retrospective study of the year 2003, of 1314 women with GDM, from 24 public health Centres in Portugal, was performed.Patients and methods: Women were divided into two groups according to their pre-pregnancy BMI: group Go – BMI ≥30 kg/m2 and group Gno BMI <30 kg/m2. The mean age of these women was 32.9±5 years (18–45), the A1c was <6% in both groups. The influence of the BMI in different...

ea0016p707 | Thyroid | ECE2008

Lack of apparent association of TSH receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism

Lueblinghoff Julia , Mueller Sandra , Sontheimer J , Paschke Ralf

Up to date, 12 patients with sporadic non-autoimmune hyperthyroidism (SNAH) caused by sporadic germline mutations in the TSHR gene have been reported. Nearly, all case reports discussed possible associations of the TSHR mutations in vitro activity (IVA) with the clinical course (CC). Therefore, we analyzed this question in a systematic review of the case reports and investigated the TSHR mutation’s IVA in selected cases.Recently, linear regre...

ea0015p42 | Clinical practice/governance and case reports | SFEBES2008

Audit of local management of primary hyperparathyroidism: would local guidelines aid management?

McGeoch Susan , Robertson Douglas , Bal Satinder , MacRury Sandra

Primary hyperparathyroidism is a common endocrine disorder. Diagnosis is more frequently made where calcium testing forms part of routine screening bloods. The clinical profile has shifted from a symptomatic disorder with hypercalcaemic symptoms, kidney stones and overt bone disease towards a more asymptomatic state. The National Institutes of Health (NIH) have produced guidelines on diagnosis and management of primary hyperparathyroidism but no UK guidelines are in existence....

ea0056p334 | Diabetes (to include epidemiology, pathophysiology) | ECE2018

Evolution of the degree of glycemic control in a cohort of patients with type 2 diabetes mellitus. study to 26 weeks

Herranz-Antolin Sandra , Alvarez-de Frutos Visitacion , Torralba Miguel

Objective: To evaluate the evolution of glycemic control in a cohort of patients with type 2 diabetes mellitus (T2DM) after its assessment in endocrinology.Methods: Prospective cohort study. 465 patients with T2DM who were not followed up at an endocrinology clinic were included. This study was approved by the Ethics and Clinical Research Committee of the University Hospital of Guadalajara.Results: Mean age was 63.4±12.5 years...

ea0099p468 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Weaning timing impact on adipose tissue remodelling in mice

Dufour Damien , Bryne Sandra , Collas Philippe , Charlotte Boccara , Briand Nolwenn

The adipose tissue is an endocrine organ distributed over multiple depots and broadly categorised into two main subtypes: white adipose tissue which stores energy as lipids and brown adipose tissue which dissipates energy in the form of heat. Adipocytes from the white depots are able to switch from a white to a brown-like phenotype, a process called beiging. This phenomenon is stimulated by cold exposure or sympathetic nervous system activation and is associated with improved ...

ea0081oc4.5 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Real-world injection experience and use of independent injection among patients using lanreotide autogel/depot (LAN) prefilled syringe or octreotide long-acting release (OCT) to treat acromegaly or neuroendocrine tumors (NETs): international PRESTO 2 survey

Webb Susan , O'Toole Dermot , Kunz Pamela , Houchard Aude , Boiziau Sandra , Ribeiro-Oliveira Antonio , Prebtani Ally

Introduction: Long-acting (LA) somatostatin analog (SSA) therapy is a common first-line medical treatment for acromegaly and NETs. There are limited real-world data on patients’ injection experience with the latest LA SSA devices/formulations.Aims: To compare the injection experience of patients with acromegaly or NETs who were receiving treatment with LAN prefilled syringe vs OCT syringe.Methods: A 2021 e-survey of adults wit...

ea0081p164 | Pituitary and Neuroendocrinology | ECE2022

Links between posterior pituitary activity, other endocrine abnormalities and psychometric profile in anorexia nervosa: a multimodal evaluation

Galusca Bogdan , Emmanuelle Doua Singoh Sandra , Germain Natacha , Mannel Merabet , Jerome Redoute , Boutet Claire , Catherine Massoubre

Introduction: Opioid system activity was found disturbed in several reward circuit areas in restrictive anorexia nervosa (AN) patients but also surprisingly at the pituitary level. However, the potential role of this specific abnormality of pituitary in AN physiopathology remains unclear or unknown.Objectives: The first aim was to find the exact pituitary location (posterior and/or anterior) of this disturbed opioid activity and then to study the link be...

ea0081p481 | Thyroid | ECE2022

Unexpected alterations in thyroid status: a case of alemtuzumab-induced Graves’ disease with fluctuating course

Filipa Araujo Barbara , Lavrador Mariana , Araujo Catia , Ribeiro Ana , Paiva Sandra , Paiva Isabel

Introduction: Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved for the treatment of relapsing−remitting multiple sclerosis (RRMS). Through an immune reconstitution mechanism, it leads to thyroid autoimmunity in 35% of cases, with Graves’ disease (GD) being the most common presentation. Alemtuzumab-induced GD exhibits distinctive clinical and immunological features, with rarely reported cases of fluctuating thyroid status with documented both blockin...

ea0081ep115 | Adrenal and Cardiovascular Endocrinology | ECE2022

Paraneoplastic Cushing’s syndrome in metastatic poorly differentiated carcinoma of the kidney

Ghenoiu Sandra , Constantin Teodor , Serban Costel Daniel , Capatina Cristina , Poiana Catalina

Introduction: Paraneoplastic Cushing’s syndrome is attributed to ectopic ACTH release from a non-pituitary tumor. The lung is frequently the primary site of the underlying neoplasm but sometimes, in cases of advanced metastatic disease, determining the origin may be challenging.Case presentation: A70-year-old man was reffered to our centre for generalised bone pain, lethargy, and important weight loss in the last six months. Before admission, a cont...

ea0081ep149 | Calcium and Bone | ECE2022

Bone mineral density in patients with addison disease versus congenital adrenal hyperplasia

Lavrador Mariana , Araujo Barbara Filipa , Carreira Ana , Paiva Sandra , Barros Luisa , Paiva Isabel

Introduction: The treatment of Primary Adrenal Insufficiency involves the chronic use of glucocorticoids. The balance between the dose needed to supply the cortisol deficit and the possible consequences of overtreatment is a challenge. In patients with Addison disease (AD), androgens deficiency is an additional factor for osteoporosis.Objective: To evaluate if there are differences in bone mineral density (BMD) in patients with Addison’s disease ver...